Please ensure Javascript is enabled for purposes of website accessibility

Why ImmunoGen Shares Are Sinking Today

By Keith Speights - Feb 18, 2020 at 11:26AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors appear to be taking profits off the table after the biotech's positive Q4 update.

What happened

Shares of ImmunoGen (IMGN -2.28%) were sinking 11.1% lower as of 11:03 a.m. EST on Tuesday. The decline appears to be the result of profit-taking following the biotech's blowout fourth-quarter results announced on Friday. ImmunoGen handily beat Wall Street's top- and bottom-line estimates for Q4. It also provided full-year 2020 guidance that was above analysts' expectations.

So what

Today's movement is only noise. For that matter, so was ImmunoGen's big jump in share price on Friday. What really matters for ImmunoGen is what matters for most biotech stocks -- achieving pipeline success.

Female scientist holding two test tubes

Image source: Getty Images.

ImmunoGen has enjoyed some successes in the past. For example, the biotech licensed its antibody-drug conjugate (ADC) technology to Roche Holdings for the development of breast cancer drug Kadcyla. Now, though, ImmunoGen's hopes ride on experimental ADC mirvetuximab soravtansine.

The company expects to enroll the first patient in the first quarter of 2020 in its pivotal Soraya clinical study evaluating mirvetuximab as a second-line treatment for ovarian cancer. ImmunoGen is also enrolling patients in its late-stage Mirasol study.

Now what

ImmunoGen anticipates reporting top-line data from the Soraya study in mid-2021. If those results are positive, the company hopes to file for FDA accelerated approval of mirvetuximab in the latter part of 2021. The Mirasol study's results, which are expected in the first half of 2022, would be used as a confirmatory study to support full approval of the drug, assuming the results are positive. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
IMGN
$4.29 (-2.28%) $0.10
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$41.36 (-2.04%) $0.86

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.